Lepu Biopharma Co., Ltd. (HKG:2157)
Hong Kong · Delayed Price · Currency is HKD 5.43
+0.27 (5.23%)
At close: Dec 19, 2025
Lepu Biopharma Revenue
Lepu Biopharma had revenue of 465.94M CNY in the half year ending June 30, 2025, with 203.44% growth. This brings the company's revenue in the last twelve months to 700.45M, up 241.55% year-over-year. In the year 2024, Lepu Biopharma had annual revenue of 367.79M with 63.21% growth.
Revenue (ttm)
700.45M CNY
Revenue Growth
+241.55%
P/S Ratio
12.77
Revenue / Employee
1.41M CNY
Employees
498
Market Cap
9.80B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 367.79M | 142.44M | 63.21% |
| Dec 31, 2023 | 225.35M | 209.78M | 1,347.16% |
| Dec 31, 2022 | 15.57M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |